

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendoc⦠read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
$1.51
Price-0.66%
-$0.01
$110.219m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$1.200m
+16.7%
1y CAGR+5.6%
3y CAGR-20.8%
5y CAGR-$28.315m
+5.7%
1y CAGR+2.1%
3y CAGR-65.2%
5y CAGR-$0.79
+24.8%
1y CAGR+14.0%
3y CAGR-40.7%
5y CAGR-$11.973m
$10.139m
Assets$22.112m
Liabilities$17.554m
Debt173.1%
-0.4x
Debt to EBITDA-$27.782m
+22.3%
1y CAGR+15.1%
3y CAGR-0.5%
5y CAGR